Quantcast

Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr Instagram
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
October 26, 2014, 03:46:37 AM

Login with username, password and session length


Members
  • Total Members: 23787
  • Latest: rvarona
Stats
  • Total Posts: 643609
  • Total Topics: 48971
  • Online Today: 159
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online
Users: 3
Guests: 132
Total: 135

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Ribavirin & EPO in HIV/HCV coinfection  (Read 808 times)

0 Members and 1 Guest are viewing this topic.

Offline Mishma

  • Member
  • Posts: 190
    • Marquis de Vauban
Ribavirin & EPO in HIV/HCV coinfection
« on: August 01, 2012, 03:46:34 PM »
From Reuters Health Information
High-Dose Ribavirin Plus EPO No Extra Help Against HCV in HIV

http://www.medscape.com/viewarticle/768340?src=nl_topic
By Robert Saunders


NEW YORK (Reuters Health) Jul 30 - Intensified ribavirin dosing given along with erythropoietin (EPO) does not improve virologic response in patients with chronic hepatitis C virus and coexisting HIV infection, Spanish researchers have found.

The effect of ribavirin on sustained virologic response that was seen in many prior studies was not seen in the PERICO trial, co-investigator Dr. Pablo Barreiro told Reuters Health. "Nor was (there) a benefit of greater RBV doses," he added.

Dr. Barreiro, of Hospital Carlos III, Madrid, and colleagues point out in their paper in the Journal of Infectious Diseases online July 17 that the combination of peginterferon-alpha and ribavirin for treating chronic hepatitis C leads to cures in 25%-50% of HCV/HIV-coinfected patients.

Higher ribavirin exposure can improve this rate, but anemia often limits that strategy, prompting the PERICO researchers to explore the preemptive use of erythropoietin while doubling the first few doses of ribavirin.

They randomly assigned 357 patients with HCV and HIV infection who were naive to interferon to receive peginterferon-alpha-2a and either standard ribavirin (1,000 or 1,200 mg/day depending on weight) or ribavirin induction at 2,000 mg/day along with subcutaneous erythropoietin during the first four weeks. Thereafter, standard ribavirin was given until completion of therapy.

A total of 251 patients completed the planned course of treatment, and 160 attained a sustained virologic response. On an intention-to-treat basis, the SVR rate was 43% in the induction arm and 47% in the standard arm (p=0.4), the investigators found.

"Unexpectedly, mean ribavirin trough concentration at week four was comparable in both treatment arms," they report. Erythropoietin (EPO) may be the reason for this and for the lack of difference in virologic response, Dr. Barreiro explained in his emailed comments.

"Use of EPO may have blunted (the) ribavirin effect, as red cells sequester free-active ribavirin," he said. "Practical lessons may be that the association between anemia and SVR could be related to greater ribavirin exposure. Therefore EPO should be used with caution, particularly in the first weeks of hepatitis C therapy."

He and his colleagues conclude: "While awaiting ... the arrival of new direct-acting antivirals against HCV, it seems worth to ensure maximal ribavirin exposure when treating HIV/HCV-coinfected patients, limiting the indication of erythropoietin only to patients that develop severe anemia on therapy."

Asked for his take on the study, Dr. Amalio Telenti told Reuters Health, "It represents a valid, if minor addition to the field."

Dr. Telenti, Professor of Medical Virology at the University of Lausanne, Switzerland, has extensive experience of HCV coinfection in the Swiss HIV Cohort Study.

The current study, he explained in his emailed remarks, "includes both viral genotypes 1/4 and 2/3 infected individuals. The majority are actually genotype 1, for whom the treatment paradigm has been profoundly changed by the recent availability of the HCV protease inhibitors."

Thus, he concluded, "The paper will have limited impact on that particular difficult-to-treat group of individuals."
2016 CD4 25% UD (less than 20). 27+ years positive. Isentress, Truvada, Acyclovir, Clonazepam, Zolpidem, Bupropion, Lisinopril, Pravastatin, Quetiapine, Doxcycline, Testosterone, Suatriptan/Naproxen, Restasis, Dorzolamide, Latanoprost, Asprin, lortab, Levothyroxine, Fioricet, Restasis, Triamclinolone, Nitrostat.

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.